Delcath Systems, Inc. - Common Stock (DCTH)

New site additions and rising treatment volume drove a strong quarter.

Delcath Systems (NASDAQ:DCTH) reported record third-quarter revenue of $35.1 million, up 71% from a year earlier, as use of its HEPZATO KIT increased across U.S. treatment centers. The company also raised its full-year revenue outlook and reported higher net income and positive operating cash flow.

Delcath Systems, Viking Therapeutics and AxoGen show growth potential backed by analyst Moderate Buy ratings and strong institutional ownership, despite risks like dilution and patent cliffs.

Delcath Systems (NASDAQ:DCTH) reported second-quarter 2026 revenue of $29.1 million, up from $24.2 million a year earlier, as growth in HEPZATO KIT sales supported continued commercial expansion and investment in clinical programs beyond metastatic uveal melanoma. HEPZATO KIT revenue totaled $27.1

Delcath (DCTH) Q1 2026 Earnings Transcript

Delcath (DCTH) Q4 2025 Earnings Call Transcript

Delcath Systems reported Q3 2025 revenue below estimates but met earnings targets. The interventional oncology firm showed strong product growth and clinical progress.

A fundamental and technical analysis of (NASDAQ:DCTH): Why the high growth investor may take a look at DELCATH SYSTEMS INC (NASDAQ:DCTH).

U.S. stock futures were lower this morning, with the Dow futures falling over 100 points on Thursday.